drugset / Trial / NCT07384429

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

NCT07384429

Phase 4 Not yet recruiting 44 enrolled YangPan Eisai China Inc. · collabNanjing University · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.

Timeline

Start
2026-08-19
Primary completion
2026-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lemborexant Small molecule 5 mg Oral